Growth Inhibitory Activity of Indian Terminalia spp. against the Zoonotic Bacterium Bacillus anthracis

groupview

Abstract
Pharmacognosy Communications,2016,6,1,2-9.
Published:December 2015
Type:Original Article

Growth Inhibitory Activity of Indian Terminalia spp. against the Zoonotic Bacterium Bacillus anthracis

Mitchell Henry Wright,1 Reece Courtney,1,2 Anthony Carlson Greene,1 Ian Edwin Cock1,2*

1School of Natural Sciences, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Queensland 4111, AUSTRALIA.

2Environmental Futures Research Institute, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Queensland 4111, AUSTRALIA.

Abstract:

Introduction: Anthrax is a zoonotic disease caused by the soil bacterium Bacillus anthracis. It has an extremely high mortality rate if untreated. Terminalia spp. have a long association with the treatment of various ailments, including bacterial infections although they have not been tested for the ability to inhibit the growth of B. anthracis. Methods: Solvent extracts were prepared using Terminalia spp. known to inhibit microorganism growth. The antibacterial potential of the extracts were investigated by disc diffusion assay to determine the growth inhibitory potential against an environmental strain of B. anthracis. Their MIC values were calculated to quantify and compare their relative efficacies. Toxicity was determined using the Artemia franciscana nauplii bioassay. Results: Extracts prepared from several Indian Terminalia spp. displayed potent antibacterial activity in the disc diffusion assay against B. anthracis. The methanolic T. chebula fruit extract was particularly effective at inhibiting microbial growth, with MIC values against B. anthracis of 166 μg/mL (<2 μg impregnated in the disc). The aqueous T. chebula extract, as well as T. catappa and T. arjuna methanolic extracts, were also good growth inhibitors with MIC’s generally <2500 μg/mL (<25 μg impregnated in the disc). All other plant extracts were either inactive or of only low inhibitory activity. None of the extracts were deemed toxic, with all recorded LC50 values substantially>1000 μg/mL. Conclusion: The potent growth inhibitory activity of the methanolic T. chebula fruit extract against B. anthracis indicates its potential in the treatment and prevention of anthrax. Furthermore, due to its low toxicity,its use may extend to all forms of the disease (cutaneous, inhalation or gastrointestinal) and may extend to live stock as well as humans.

Founded:  In 2004, as the PHCOG.NET – a non-profit private organization dedicated to Natural Products Research leading to develop promising drugs. Our main mission is to make information on herbal drug research readily available in different formats to suit the individual needs.

Pharmacognosy Communications [Phcog Commn.] is a new quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the  publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.

The journal aims to cater the latest outstanding developments in the field of pharmacognosy and natural products and drug design covering but not limited to the following topics:

  • Pharmacognosy and pharmacognistic investigations
  • Research based ethnopharmacological evaluations
  • Biological evaluation of crude extracts, essential oils and pure isolates
  • Natural product discovery and evaluation
  • Mechanistic studies
  • Method and technique development and evaluation
  • Isolation, identification and structural elucidation of natural products
  • Synthesis and transformation studies

Distinctions:  The most widely read, cited, and known Pharmacognosy Communications and website is well browsed with all the articles published. More than 20,000 readers in nearly every country in the world each month

Aim and Scope | Editorial Board | Indexed & Abstracted | Instruction to Authors | Manuscript Submission & Charges

Subjects Covered : Natural Products, Pharmacognosy, Phytochemistry, Marine Pharmacognosy and Zoo Pharmacognosy
ISSN :2249-0159 (Print) ; 2249-0167 (Online) Frequency : Quarterly Rapid at a time publication (4 issues/year)

Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online  publication is 45 days.
Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.